How have COEPW shares performed in 2024?

Coeptis Therapeutics' stock was trading at $0.0310 at the beginning of the year. Since then, COEPW shares have decreased by 29.0% and is now trading at $0.0220. View the best growth stocks for 2024 here .

How do I buy shares of Coeptis Therapeutics?

Shares of COEPW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:COEPW

Coeptis Therapeutics (COEPW) Stock Price, News & Analysis

→ Charles Payne’s Gift to Stock Investors (From Unstoppable Prosperity) (Ad)

Free COEPW Stock Alerts

$0.02

0.00 (0.00%)

(As of 04/29/2024 ET)

Compare

Today's Range: $0.02
▼
$0.02
50-Day Range: $0.02
▼
$0.05
52-Week Range: $0.02
▼
$0.15

Volume: 3,955 shs
Average Volume: 26,686 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials SEC Filings Social Media

Get Coeptis Therapeutics alerts:

Ad Banyan Hill Publishing

Nvidia CEO Says It Will Be “the Next Revolution” Beyond AI

Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.

Click on Adam's shiny forehead for more details.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.

COEPW Stock Price History

30 days | 90 days | 365 days | Advanced Chart

COEPW Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive COEPW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coeptis Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:COEPW
CUSIP: N/A
CIK: 1759186
Web: coeptispharma.com
Phone: 724 934 6467
Fax: N/A
Employees: 4
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. David Mehalick (Age 54)
Co-Founder, Chairman, CEO & Pres
Comp: $361.62k
Ms. Christine Elise Sheehy (Age 56)
Co-Founder and VP of Compliance & Corp. Sec.
Comp: $226k
Mr. Daniel Alexander Yerace (Age 40)
Co-Founder, VP of Operations & Director
Comp: $360.35k
Mr. Brian Cogley M.B.A. (Age 37)
Chief Financial Officer

Key Competitors

View All Competitors

COEPW Stock Analysis - Frequently Asked Questions

How have COEPW shares performed in 2024?: Coeptis Therapeutics' stock was trading at $0.0310 at the beginning of the year. Since then, COEPW shares have decreased by 29.0% and is now trading at $0.0220.
View the best growth stocks for 2024 here.
How do I buy shares of Coeptis Therapeutics?: Shares of COEPW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:COEPW) was last updated on 4/29/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial